58 related articles for article (PubMed ID: 37190893)
21. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
22. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
23. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
Ishikawa C; Mori N
Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
[TBL] [Abstract][Full Text] [Related]
24. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
25. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
26. NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma.
Huang X; Cao W; Yao S; Chen J; Liu Y; Qu J; Li Y; Han X; He J; Huang H; Zhang E; Cai Z
Cell Death Dis; 2022 Mar; 13(3):197. PubMed ID: 35236820
[TBL] [Abstract][Full Text] [Related]
27. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.
Zhou Z; Van der Jeught K; Fang Y; Yu T; Li Y; Ao Z; Liu S; Zhang L; Yang Y; Eyvani H; Cox ML; Wang X; He X; Ji G; Schneider BP; Guo F; Wan J; Zhang X; Lu X
Nat Biomed Eng; 2021 Nov; 5(11):1320-1335. PubMed ID: 34725507
[TBL] [Abstract][Full Text] [Related]
28. ALCAM-EGFR interaction regulates myelomagenesis.
Luo H; Zhang D; Wang F; Wang Q; Wu Y; Gou M; Hu Y; Zhang W; Huang J; Gong Y; Pan L; Li T; Zhao P; Zhang D; Qu Y; Liu Z; Jiang T; Dai Y; Guo T; Zhu J; Ye L; Zhang L; Liu W; Yi Q; Zheng Y
Blood Adv; 2021 Dec; 5(23):5269-5282. PubMed ID: 34592762
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle control in cancer.
Matthews HK; Bertoli C; de Bruin RAM
Nat Rev Mol Cell Biol; 2022 Jan; 23(1):74-88. PubMed ID: 34508254
[TBL] [Abstract][Full Text] [Related]
30. CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M; Zhang L; Hei R; Li X; Cai H; Wu X; Zheng Q; Cai C
Am J Cancer Res; 2021; 11(5):1913-1935. PubMed ID: 34094661
[TBL] [Abstract][Full Text] [Related]
31. CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.
Li H; Cui R; Ji M; Jin SY
Leuk Res; 2021 Jul; 106():106575. PubMed ID: 33878513
[TBL] [Abstract][Full Text] [Related]
32. Multiple myeloma.
van de Donk NWCJ; Pawlyn C; Yong KL
Lancet; 2021 Jan; 397(10272):410-427. PubMed ID: 33516340
[TBL] [Abstract][Full Text] [Related]
33. Role of deubiquitinating enzymes in DNA double-strand break repair.
Li Y; Yuan J
J Zhejiang Univ Sci B; 2021 Jan; 22(1):63-72. PubMed ID: 33448188
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Bass AKA; El-Zoghbi MS; Nageeb EM; Mohamed MFA; Badr M; Abuo-Rahma GEA
Eur J Med Chem; 2021 Jan; 209():112904. PubMed ID: 33077264
[TBL] [Abstract][Full Text] [Related]
36. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
[TBL] [Abstract][Full Text] [Related]
37. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer.
Harbeck N; Penault-Llorca F; Cortes J; Gnant M; Houssami N; Poortmans P; Ruddy K; Tsang J; Cardoso F
Nat Rev Dis Primers; 2019 Sep; 5(1):66. PubMed ID: 31548545
[TBL] [Abstract][Full Text] [Related]
39. Biology and therapy of multiple myeloma.
Joshua DE; Bryant C; Dix C; Gibson J; Ho J
Med J Aust; 2019 May; 210(8):375-380. PubMed ID: 31012120
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.
Ji M; Li Z; Lin Z; Chen L
Am J Cancer Res; 2018; 8(12):2402-2418. PubMed ID: 30662800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
